CXCL12 and prostate carcinoma: Similar results for Pyk2 and FAK have been observed in different cell types (hemopoietic cancer cells [35], ovarian cancer cells [36,37], smooth vascular cells [38], and prostate cancer cells [39]) following treatment with SDF-1α, IL-6, EGF, IL-8, and PDGFβ.